Intervention

bimatoprost 0.01%

ClinicalTrials.gov intervention label

Clinical trials4
Recruiting0
Common conditions3
Lead sponsors shown1

Clinical trials

4 shown
Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular HypertensionNCT02097719 · 2014-05-01
COMPLETED
An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular HypertensionNCT01881126 · 2013-06-01
COMPLETED
Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)NCT01628588 · 2010-03-01
COMPLETED
A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)NCT01632423 · 2010-02-01
COMPLETED

Trial status mix

COMPLETED4

Phase mix

PHASE42

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.